Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02187861
Registration number
NCT02187861
Ethics application status
Date submitted
9/07/2014
Date registered
11/07/2014
Date last updated
5/06/2019
Titles & IDs
Public title
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
Query!
Scientific title
A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison With BR Alone or GDC-0199 Plus Rituximab (R) in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma
Query!
Secondary ID [1]
0
0
2014-000576-26
Query!
Secondary ID [2]
0
0
BO29337
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Venetoclax
Treatment: Drugs - Bendamustine
Treatment: Drugs - Rituximab
Experimental: Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) - Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
Experimental: Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) - Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
Experimental: Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) - Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m\^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
Active comparator: Chemotherapy-Containing Cohort: Arm C (BR) - Participants will receive rituximab 375 mg/m\^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
Treatment: Drugs: Venetoclax
Venetoclax will be administered as per the schedule specified under arm description.
Treatment: Drugs: Bendamustine
Bendamustine will be administered as per the schedule specified under arm description.
Treatment: Drugs: Rituximab
Rituximab will be administered as per the schedule specified under arm description.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA)
Query!
Assessment method [1]
0
0
CMR: a score 1 (no uptake above background), 2 (uptake less than or equal to \[\<=\] mediastinum), or 3 (uptake less than \[\<\] mediastinum but \<=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites with no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [1]
0
0
6-8 weeks after Cycle 6 Day 1 (PRA) (Cycle length = 28 days)
Query!
Secondary outcome [1]
0
0
Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA
Query!
Assessment method [1]
0
0
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [1]
0
0
4-10 weeks after Cycle 6 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [2]
0
0
Percentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 1
Query!
Assessment method [2]
0
0
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (uptake \<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [2]
0
0
48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 1
Query!
Assessment method [3]
0
0
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [3]
0
0
48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Complete Response (CR) According to IRC as Per Lugano Classification, Using Computed Tomography (CT) Scan
Query!
Assessment method [4]
0
0
CR: defined as reduction of longest transverse diameter of lesion (LDi) of target nodes/nodal masses to \<=1.5 centimeters (cm), and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [4]
0
0
6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With CR According to Investigator as Per Lugano Classification, Using CT Scan
Query!
Assessment method [5]
0
0
CR: defined as reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [5]
0
0
4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Objective Response (OR) According to IRC as Per Lugano Classification, Using PET Scan
Query!
Assessment method [6]
0
0
OR was defined as CMR or Partial Metabolic Response (PMR). CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [6]
0
0
6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [7]
0
0
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET Scan
Query!
Assessment method [7]
0
0
OR was defined as CMR or PMR. CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [7]
0
0
4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [8]
0
0
Percentage of Participants With OR According to IRC as Per Lugano Classification, Using CT Scan
Query!
Assessment method [8]
0
0
OR was defined as CR or Partial Response (PR). CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: greater than or equal to (\>=) 50 percent (%) decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [8]
0
0
6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [9]
0
0
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using CT Scan
Query!
Assessment method [9]
0
0
OR was defined as CR or PR. CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: \>=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Query!
Timepoint [9]
0
0
4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Query!
Secondary outcome [10]
0
0
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan
Query!
Assessment method [10]
0
0
OR was defined as CMR/CR or PMR/PR. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing).
Query!
Timepoint [10]
0
0
Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Query!
Secondary outcome [11]
0
0
Duration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan
Query!
Assessment method [11]
0
0
DOR was defined as time from CMR/CR or PMR/PR until progressive disease (PD) or death due to any cause. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing). DOR was calculated using Kaplan-Meier method.
Query!
Timepoint [11]
0
0
From CMR or PMR until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Query!
Secondary outcome [12]
0
0
Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death
Query!
Assessment method [12]
0
0
PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.
Query!
Timepoint [12]
0
0
Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Query!
Secondary outcome [13]
0
0
Progression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan
Query!
Assessment method [13]
0
0
PFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) until the date of disease progression, or death due to any cause. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. PFS was calculated using Kaplan-Meier method.
Query!
Timepoint [13]
0
0
Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy
Query!
Assessment method [14]
0
0
PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.
Query!
Timepoint [14]
0
0
Baseline until disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first (assessed up to approximately 2.5 years)
Query!
Secondary outcome [15]
0
0
Event-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan
Query!
Assessment method [15]
0
0
EFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to the date of disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. EFS was calculated using Kaplan-Meier method.
Query!
Timepoint [15]
0
0
Baseline until disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first (assessed up to approximately 2.5 years)
Query!
Secondary outcome [16]
0
0
Percentage of Participants Who Died Due to Any Cause
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Baseline until death due to any cause (assessed up to approximately 2.5 years
Query!
Secondary outcome [17]
0
0
Overall Survival (OS)
Query!
Assessment method [17]
0
0
OS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to death due to any cause. For participants who are alive, OS was censored at the last contact. OS was calculated using Kaplan-Meier method.
Query!
Timepoint [17]
0
0
Baseline until death due to any cause (assessed up to approximately 2.5 years)
Query!
Secondary outcome [18]
0
0
Apparent Clearance (CL) of Venetoclax
Query!
Assessment method [18]
0
0
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Query!
Timepoint [18]
0
0
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Query!
Secondary outcome [19]
0
0
Apparent Volume of Distribution (Vd) of Venetoclax
Query!
Assessment method [19]
0
0
Vd was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Query!
Timepoint [19]
0
0
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Query!
Secondary outcome [20]
0
0
Time to Maximum Plasma Concentration (Tmax) of Venetoclax
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Query!
Secondary outcome [21]
0
0
Maximum Plasma Concentration (Cmax) of Venetoclax
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Query!
Secondary outcome [22]
0
0
Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax
Query!
Assessment method [22]
0
0
Area under the plasma concentration versus time curve from zero to the last measured concentration (AUClast).
Query!
Timepoint [22]
0
0
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Query!
Secondary outcome [23]
0
0
Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax
Query!
Assessment method [23]
0
0
Area under the plasma concentration versus time curve from time 0 (pre-dose) to 8 hours post dose (AUC0-8h).
Query!
Timepoint [23]
0
0
Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Query!
Eligibility
Key inclusion criteria
* Participants must have histologically confirmed follicular lymphoma (FL) of Grade 1, 2, or 3a
* Participants must have received at least one prior therapy for FL
* For participants potentially receiving chemotherapy: if the participant has received prior bendamustine, response duration must have been greater than (>) 1 year
* At least one bi-dimensionally measurable lesion on imaging scan defined as >1.5 centimeters (cm) in its longest dimension
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
* Adequate hematologic function
* For female participants of childbearing potential and male participants with female partners of childbearing potential, agreement to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception throughout the course of study treatment and for at least 30 days after the last dose of venetoclax and 12 months after the last dose of rituximab, whichever is longer
* Confirmed availability of archival or freshly biopsied tumor tissue meeting protocol-defined specifications prior to study enrollment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
* Contraindication to potential treatment agents
* Ongoing corticosteroid use >30 milligrams per day (mg/day) of prednisone or equivalent. Participants receiving corticosteroid treatment with less than equal to (</=) 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks duration prior to randomization (Cycle 1 Day 1)
* Primary central nervous system (CNS) lymphoma
* Vaccination with live vaccines within 28 days prior to treatment
* Chemotherapy or other investigational therapy within five half-lives of a biologic agent with a minimum of 28 days prior to the start of Cycle 1
* History of other malignancy that could affect compliance with the protocol or interpretation of results
* Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the participant
* Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1
* Requires the use of warfarin
* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
* Presence of positive test results for hepatitis B surface antigen or hepatitis C virus (HCV) antibody
* Participants who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation
* Participants with occult or prior hepatitis B virus (HBV) infection may be included if HBV deoxyribonucleic acid (DNA) is undetectable at screening. These participants must be willing to undergo monthly HBV DNA test until at least 12 months after the last treatment cycle
* Known infection with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1)
* Pregnant or lactating
* Recent major surgery (within 6 weeks before the start of Cycle 1 Day 1), other than for diagnosis
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/03/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
163
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital; Medical Oncology - Camperdown
Query!
Recruitment hospital [2]
0
0
St George Hospital - Kogarah, New South Wales
Query!
Recruitment hospital [3]
0
0
Royal North Shore Hospital - St. Leonards
Query!
Recruitment hospital [4]
0
0
Westmead Hospital; Haematology - Sydney
Query!
Recruitment hospital [5]
0
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment hospital [6]
0
0
Townsville General Hospital - Douglas
Query!
Recruitment hospital [7]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [8]
0
0
Queen Elizabeth Hospital; Haematology - Woodville South
Query!
Recruitment hospital [9]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [10]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah, New South Wales
Query!
Recruitment postcode(s) [3]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [4]
0
0
2145 - Sydney
Query!
Recruitment postcode(s) [5]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [6]
0
0
4184 - Douglas
Query!
Recruitment postcode(s) [7]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [8]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [9]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [10]
0
0
3168 - Clayton
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Virginia
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
West Virginia
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Antwerpen
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Brugge
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Bruxelles
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Alberta
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
British Columbia
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Saskatchewan
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Angers
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Clermont Ferrand cedex 1
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Creteil
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Dijon
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Le Mans
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Montpellier
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Pierre Benite
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Chemnitz
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Dessau-Roßlau
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Dresden
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Essen
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Jena
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Koeln
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Lübeck
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Mainz
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Ulm
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Würzburg
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Emilia-Romagna
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Lombardia
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Piemonte
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Toscana
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
Blackpool
Query!
Country [43]
0
0
United Kingdom
Query!
State/province [43]
0
0
Leeds
Query!
Country [44]
0
0
United Kingdom
Query!
State/province [44]
0
0
Leicester
Query!
Country [45]
0
0
United Kingdom
Query!
State/province [45]
0
0
London
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Manchester
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
Oxford
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
AbbVie
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This open-label, international, multicenter study will investigate the safety and efficacy of venetoclax (GDC-0199) in combination with bendamustine plus rituximab (venetoclax + BR) compared with BR alone in participants with relapsed and refractory fNHL, comparing two chemotherapy-containing regimens (Chemotherapy-Containing Cohort). In addition, an exploratory analysis of the safety and efficacy of venetoclax in combination with rituximab (venetoclax + rituximab), a chemotherapy-free regimen, will be performed (Chemotherapy-Free Cohort). Assignment to the Chemotherapy-Containing or Chemotherapy-Free Cohort will be decided at the discretion of the Investigator, unless one of the cohorts is not open to enrollment; in which case, participants may be enrolled only to the open cohort. The first 6 participants enrolled in the Chemotherapy-Containing Cohort (or more if required) will comprise the Safety Run-In group for Treatment Arm B, dosing venetoclax at 600 milligrams (mg) in combination with BR. Once a dose has been chosen from the Safety Run-In Period, randomization to the two treatment arms of the Chemotherapy-Containing Cohort (Arms B and C) will begin.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02187861
Query!
Trial related presentations / publications
Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, Le Du K, Arthur C, Pro B, Gritti G, Crump M, Petrich A, Samineni D, Sinha A, Punnoose EA, Szafer-Glusman E, Spielewoy N, Mobasher M, Humphrey K, Kornacker M, Hiddemann W. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020 Dec 3;136(23):2628-2637. doi: 10.1182/blood.2020005588.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT02187861
Download to PDF